Our vision is to be The Retina Company and recognized as a leading provider of devices to eye care professionals for improved patient care. Our core devices produce ultra-widefield (UWF™), high resolution optomap images of approximately 82% or 200◦ of the retina, something no other device is capable of doing in a single capture. An optomap image provides a bigger picture and more clinical information which facilitates the early detection, management and effective treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy and age-related macular degeneration. Click here to contact Optos.
With traditional, small-field, and even widefield retinal imaging, only 10-100⁰ of the retina can be captured in a single image. optomap is the only true, clinically validated, ultra-widefield retinal image than can capture 82% or 200⁰ of the retina, in a single capture, in each imaging modality – an increase of 50% over the next closest imaging device1. With optomap auto-montage, up to 97% or 220⁰ of the retina can be imaged with the multi-capture, montaging functionality.
optomap offers unparalleled views of the retina which provide eye care professionals with the following:
- The only anatomically correct 200⁰ or 82% image of the retina
- Simultaneous view of the central pole, mid-periphery and periphery
- Integrated hardware & software platform
- Multiple retinal imaging modalities to see more, discover more, and treat more patient diseases and pathologies, more effectively
- With more than 400 published and ongoing clinical trials, as well as thousands of case studies and testimonials, show the long-term value of optomap imaging in diagnosis, treatment planning and patient engagement
Optos introduced ultra-widefield (UWF™) retinal imaging to enable eyecare professionals to discover, diagnose, document and treat ocular pathology that may first present in the periphery – pathology which may go undetected using traditional examination techniques and equipment. Our UWF, high resolution retinal imaging devices each image of more than 80% or 200˚ of the retina in a single capture. Our complete list of ultra-widefield retinal imaging devices can be found here.
For a better understanding of the differences between optomap versus widefield or traditional retinal imaging devices, please watch the videos below.
Optos has a range of retinal imaging devices that support different customer segments and patient needs such as wellness screening carried out by optometrists in primary care settings or more exacting imaging in secondary care practices that are clinically managing a patient base with advanced ocular disease. Our most advanced imaging devices for disease management and treatment support ophthalmologists and retinal specialists in the medical care market.
The latest products, Daytona and California represents the newest generation of Optos ultra-widefield retinal imaging technology and have been converted to desktop models while still providing high resolution images. For both devices, the ergonomic body is designed to increase patient comfort, as well as make it easier to correctly position the eye for image capture. All image modalities; colour, red-free and autofluorescence (AF) are included in both devices. California features fluorescein angiography (FA) and our newest UWF imaging modality, indocyanine green angiography. ICG is used for imaging the choroidal vasculature which is important for the diagnosis, management and treatment of certain conditions such as neovascular age-related macular degeneration (AMD) and disorders with choroidal neovascular membranes.
Optos is committed to utilising the latest technology to manufacture new products and software that support optomap as a standard of care therefore helping eyecare professionals around the world save sight and lives. Furthermore the company continues to strengthen its clinical evidence and expand its disease indications to demonstrate the importance of imaging the entire retina.